The management of hormone receptor-positive (HR+) early-stage breast cancer has been revolutionized by the widespread use of adjuvant endocrine therapy (AET), a class of treatment that has unequivocally improved recurrence-free and overall survival outcomes [8]. This evidence concerns the gene NR4A1 and breast carcinoma.